A1 Refereed original research article in a scientific journal
Expression of toll-like receptors in recurrent pleomorphic adenoma and carcinoma ex pleomorphic adenoma
Authors: Jauhiainen, Maria K; Markkanen, Anttoni; Atula, Timo; Aro, Katri; Haglund, Caj; Söderlund-Venermo, Maria; Mäkitie, Antti A; Sinkkonen, Saku T; Hagström, Jaana
Publisher: John Wiley & Sons
Publication year: 2025
Journal: APMIS
Journal name in source: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
Journal acronym: APMIS
Volume: 133
Issue: 1
ISSN: 0903-4641
eISSN: 1600-0463
DOI: https://doi.org/10.1111/apm.13505
Web address : https://onlinelibrary.wiley.com/doi/10.1111/apm.13505
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/478219105
Pleomorphic adenoma (PA) is a benign salivary gland tumour that may recur or undergo malignant transformation (CXPA). Toll-like receptors (TLR) mediate immune responses triggered by various agents such as viruses and are related to tumour formation either by stimulating or suppressing their growth, with variation across different tumour entities. We compared TLR immunohistochemical expression in PA, its recurrent counterparts and CXPA and evaluated the effect of virus presence in these tumours. We studied the expression of TLR-2, -3, -5, -7 and -9 in 25 PA, 34 recurrent PA and 15 CXPA tumour samples. In addition, we examined the TLR expression levels in the presence and absence of herpes-, polyoma- and parvovirus DNA in a subset of tumours (n = 20). CXPA expressed significantly more TLR-5 and TLR-9 in the nucleus, cytoplasm and cell membrane compared with benign PA. The presence of virus DNA did not notably affect the TLR expression. TLR expression patterns seem to reflect tumour behaviour but are independent of the presence of viruses tested in this study.
Downloadable publication This is an electronic reprint of the original article. |
Funding information in the publication:
The study was supported by HusLab, and by State Funding for the Helsinki University Hospital (Y780023053, 2021338, and 2021220), and the University of Helsinki Doctoral Programme of Clinical Research.